You are here: Industry Insights > Market News > SMS Life Sciences India gets DSIR recognition for Hyderabad R&D unit

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Butterfly Valve

Constant-Pressure Modulating Valve

Aseptic Sampling Valve

Sanitary Sampling Valve

Rotary Valve

Rotary Valve Tablet

SMS Life Sciences India gets DSIR recognition for Hyderabad R&D unit

expresspharmaFebruary 09, 2021

Tag: SMS Life Sciences , DSIR , Sanathnagar

Favorites

SMS Life Sciences informed through a statement that the Department of Scientific and Industrial Research (DSIR) of Government of India, Ministry of Science and Technology, New Delhi has accorded recognition to its in-house Research and Development (R&D) Unit(s) located at Sanathnagar, Hyderabad, Telangana.

The aforesaid recognition will entitle R&D unit of the company to avail Customs/Central Excise duty exemption on the purchase/import of equipment, instruments, spares thereof, consumables etc., used for R&D activities. The said registration is valid upto March 31, 2023.

Previous:881 ongoing overcharging cases worth Rs 8184.19 cr under DPCO: D V Sadananda Gowda

Next:Indian pharma market expected to grow to $130 bn by 2030: Gowda

Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies

ACN NewswireAugust 02, 2025

Everest Medicines (HKEX: 1952.HK) today announced a strategic equity investment in I-Mab (NASDAQ: IMAB), under which Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash.

Alphamab Oncology Announces Anti-HER2 Biparatopic ADC JSKN003 Obtained Orphan Drug Designation from the U.S. FDA for the Treatment of GC/GEJ

PR NewswireJuly 29, 2025

Tigermed Completes Acquisition of Japanese CRO Micron

PRNewswireJuly 29, 2025

SMS Life Sciences India gets DSIR recognition for Hyderabad R&D unit | Pharmasources.com

Leo Cancer Care Receives FDA 510(k) Clearance for Marie? - A Revolutionary Upright Radiotherapy Platform

PR NewswireJuly 29, 2025

Leo Cancer Care, a leader in upright radiotherapy solutions, today announces that its flagship product, Marie?, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

亚洲欧美不卡高清在线观看,伊人久久大香线蕉午夜av,亚洲综合色区在线观看,中文在线中文a,真正免费的毛片

SMS Life Sciences India gets DSIR recognition for Hyderabad R&D unit

Related News

Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies

Alphamab Oncology Announces Anti-HER2 Biparatopic ADC JSKN003 Obtained Orphan Drug Designation from the U.S. FDA for the Treatment of GC/GEJ

Tigermed Completes Acquisition of Japanese CRO Micron

Leo Cancer Care Receives FDA 510(k) Clearance for Marie? - A Revolutionary Upright Radiotherapy Platform

You may like
More>>

亚洲欧美不卡高清在线观看,伊人久久大香线蕉午夜av,亚洲综合色区在线观看,中文在线中文a,真正免费的毛片

SMS Life Sciences India gets DSIR recognition for Hyderabad R&D unit

Related News

Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies

Alphamab Oncology Announces Anti-HER2 Biparatopic ADC JSKN003 Obtained Orphan Drug Designation from the U.S. FDA for the Treatment of GC/GEJ

Tigermed Completes Acquisition of Japanese CRO Micron

Leo Cancer Care Receives FDA 510(k) Clearance for Marie? - A Revolutionary Upright Radiotherapy Platform

You may likeMore>>

You may like
More>>